ABSTRACT
INTRODUCTION
Gastric cancer (GC), the fourth most common and the second most deadly cancer worldwide, is particularly prevalent in developing countries [1] . Although significant progress has been achieved in multimodal therapy strategies, such as combination therapy with surgery, chemotherapy, radiotherapy, or targeted therapy, the prognosis still remains poor with 5-year overall survival rates less than 25% [2] . Biomarkers for early diagnosis are important in deciding therapeutic options, as well as improving treatment efficiency and prognosis prediction [3] .
Genetic factors play crucial roles in initiation of carcinogenesis and cancer development. Although gastric carcinogenesis undergoes highly complicated processes (e.g., abrogated gene expression, abnormal cell proliferation, resistance to apoptosis, dedifferentiation, enhanced survival, escape of immune surveillance, and metastasis) [4, 5] , abrogation of gene expression or function caused by genetic changes (i.e., deletion, amplification and mutation) is the main force driving normal gastric cells into cancer cells. It has been shown that dysfunctions of one-carbon metabolism associated genes contribute to carcinogenesis via affecting DNA methylation, synthesis and repair [6] . One-carbon metabolism (OCM) pathway is a centered pathway involved in folate metabolism and DNA synthesis. It contains several crucial enzymatic reactions from folate uptake to synthesis of S-adenosylmethionine (SAM) [7] . Methylenetetrahydrofolate reductase (MTHFR) is a vitamin B2-dependent enzyme that carries out an irreversible conversion of 5,10-methylene-tetrahydrofolate (5,10-MTHF) to 5-methyl-tetrahydrofolate (5-MTHF) [8] . This is the rate-limiting step for OCM because 5,10-MTHF is the substrate for three other enzymatic reactions. Methionine synthase (MTR) catalyzes the remethylation of homocysteine to methionine [9] , the residue critical for maintaining adequate intercellular folate level. Methionine synthase reductase (MTRR) maintains MTR in its active form. Thymidylate synthase (TS) catalyzes the reductive methylation of dUMP by 5,10-MTHF to form dTMP and dihydrofolate, a rate-limiting step in DNA synthesis [10] . TS is an essential enzyme in proliferating cells and is also an important target for a variety of chemotherapeutic drugs, e.g. 5-FU.
Previous studies have identified that functional polymorphisms of these genes in the OCM pathway were associated with human cancers, including colorectal cancer, head and neck cancer, esophagus cancer, hepatocellular cancer, lung cancer, renal cell carcinoma and gastric cancer [11] [12] [13] [14] [15] [16] [17] [18] . Common variants of MTHFR (rs1801133, 677 C > T, Ala222Val; and rs1801131, 1298 A > C, Glu429Ala) reduced enzyme activity and plasma folate levels, resulting in hypomethylation [19] . Suboptimal methyl supply led to dysfunction of DNA methylation, a process highly associated with GC etiology [20] . The polymorphisms of MTR (rs1805087, 2756 A > G, Asp868Gly) and MTRR (rs1801394, 66A > G, ILe22Met), which were associated with hyperhomocysteinemia [21] , impaired remethylation of homocysteine to methionine. The copy number of 28-bp tandem repeats in the 5′-untranslated region (5′-UTR) of TS gene affected the translational efficiency [22] . In a reporter assay, the 5′-UTR of TS with 3-repeats (3R) displayed much higher luciferase activities than that with 2-repeats (2R), suggesting this tandem repeats may enhance the assembly of translational machinery or mediate more effective binding between ribosome and TS mRNA [23] . It was shown that intratumoral TS protein level was associated with the sensitivity of chemotherapy (e.g. 5-FU) [24, 25] . A novel polymorphism with 6-bp deletion of the sequence TTAAAG at nt1494 was found to be associated with decreased TS mRNA stability in the 3-untranslated region (3′-UTR) of TS gene. Therefore, the deletion suppressed its expression [26, 27] . However, whether the 5′-UTR and 3′-UTR polymorphisms interact each other and display synergistic or counteractive effects on GC have not been investigated.
The effects of polymorphisms of individual gene or combinations of two genes have been investigated on GC survival. Whether these polymorphisms would interact with each other and display certain synergistic effects have not been reported. In this study, for the first time, based on large-number clinical data analysis, we systematically investigated the comprehensive effects of polymorphisms of four genes involved in OCM pathway on the clinical outcomes of GC patients.
RESULTS

Clinical features of the study subjects
The clinical characteristics of 919 retained GC patients were described in Table 1 . The median age of the study subjects was 62.0 years (range, 28-83 years). All of the GC patients underwent the surgical resections and 297 patients received chemotherapy. 426 patients died during the 119.0 months of follow-up. The survival time was significantly related to varieties in tumor size, histological type and depth of invasion, lymph node metastasis and TNM stage (all log-rank p < 0.05). In particular, patients with tumor size >5 cm (MST, 50 months) had a 41% significantly higher risk of death (HR = 1.41, 95% CI = 1.16-1.71, p < 0.001 ) when compared with those with tumor size ≤ 5 cm (MST, 98 months). The intestinal-type patients (MST, 77 months) had a 64% significantly lower risk of death (HR = 1.36, 95% CI = 1.13-1.54, p < 0.001) than diffuse-type patients (MST, 62 months). Patients with lymph node metastasis (MST, 46 months) also had a 76% higher risk of death (HR = 1.76, 95% CI = 1.43-2.16, p < 0.001) when compared to those with no lymph node metastasis (MST, 80 months). Furthermore, as the depth of invasion and TNM stage increased, the risk of death also exhibited an obvious increase (log-rank p < 0.001).
Prolongation of patient survival with MTRR 66A > G polymorphism
The relationships between individual polymorphisms and survival of GC patients in different genetic models were assessed by Cox regression analyses. Codominant, dominant and recessive models were Table 2 ). The overall survival of GC patients with 66A > G dominant genotypes (AG + GG) was presented in Figure 1 . Heterozygote 66A > G genotypes exhibited marginal prolongation of survival of GC patients (HR = 0.883, 95% CI = 0.684-1.028, Table 2 ).
MTHFR 1298CC genotype associate with decreased risk of death
In the case of MTHFR 1298A > C polymorphism, patients with homozygote CC genotype (MST, 81 months) had a 44% significantly lower risk of death (HR = 0.440, 95% CI = 0.210-0.940) when compared with those with AA genotype (MST, 65 months). A similar result was also obtained in a recessive model (HR = 0.446, 95% CI = 0.211-0.942, Table 2 ).
In
the case of MTHFR 677C > T and other polymorphisms (MTR 2756A > G, TS 5′-UTR 2R > 3R
and 3′-UTR 6bp ins > del), no significant associations were identified between survival time and polymorphisms in any genetic models (Table 2) .
MTRR 66A > G polymorphism on protection of GC patients
To better demonstrate the protective effect of 66A > G polymorphism on GC survival in detail, we performed stratified analyses based on tumour size, tumour site, histological type, depth of invasion, lymph node metastasis, distant metastasis, TNM stage and chemotherapy. No obvious association was detected with tumor size or location in GC patients (Table 3) . Surprisingly, we detected significant protection of GA + GG genotypes in patients 
Effects of polymorphism interactions on patient survival
Considering the intricate interactions among the genes described above, we tested polymorphism interactions on Figure 2A and Figure 2B . Although the MTHFR 1298 CA + CC genotypes were not associated with overall survival in univariate analysis, significant protective effect occurred when the above were combined with TS 5′-UTR 2R3R + 3R3R genotypes (HR = 0.536, 95% CI = 0.315-0.913, log-rank p = 0.022, Table 4 ). Compared to 1298AA + TS 5′-UTR 2R2R genotypes, MST of patients with 1298 CA + CC and TS 5′-UTR 2R3R + 3R3R genotypes was extended from 30 months to 98 months ( Table 4 ). The overall survival of GC patients was obviously extended and shown in Figure 3 .
DISCUSSION
In this study, we investigated the effects of polymorphisms and their interactions in OCM pathway on survival of GC patients. The results demonstrated that the polymorphisms of MTRR 66A > G and MTHFR 1298A > C increased the survival of GC in a Chinese population. The MST of GC patients were strongly affected by MTHFR 1298A > C, TS 5′-UTR copy numbers and interactions between MTRR 66A > G and MTR 2756A > G.
DNA dysmethylation is one of the crucial events for cancer development. It is well known that hypermethylation on promoters of tumor suppressor genes causes human cancers. MTRR and MTR maintained adequate levels of methionine, which functioned as a precursor for the universal methyl group donor S-adenosylmethionine [12] . The mutation of MTRR 66A > G led to abnormal DNA methylation and altered nucleotide synthesis and repair [21] . MTRR 66A > G polymorphism has been shown to increase risk of esophageal, colorectal and lung cancer [11, 12, 14] . However, some groups reported that the polymorphism had no significant effect on colorectal and breast cancers or cervical cancer [28, 29] . Our present result showed that MTRR 66A > G polymorphism displayed a protective effect on GC among Chinese population (Table 2 and Figure 1) , which was similar to the results in prostate cancer and colon cancer [30, 31] . Clinical analysis for functional contribution of polymorphism with multiple subgroups on the basis of clinical characteristics was vital to identify the potential prognostic markers in diverse stages of cancer progression. Several other studies have also demonstrated that the clinical characteristics of GC were related to the survival of GC patients [32, 33] . Our findings indicated that patients with MTRR 66 GA + GG genotypes had better survival among subgroups that have more pronounced diffuse type, greater depth of invasion (T2/T3/T4), higher-level lymph node metastasis (N1/N2/ N3), advanced TNM stages (III/IV), and 5-FU treatment. The results indicated that MTRR 66G allele improved the survival of GC patients. It has been proposed that MTR activity could not be maintained at a high level because residue Ile22 to Met22 switch of MTRR caused by the polymorphism reduced it activity [34] . Therefore, MTR could not effectively generate methionine for DNA methylation. We postulated that reduced methylation [35] . A meta-analysis showed that MTR 2756GG genotype obviously increased cancer risk in Asian populations, whereas a significantly reduced risk was observed in European populations [36] . Some other studies, consistent with our result among GC patients, demonstrated that no association was identified in colon cancer risk [37, 38] . In this study, we did not observe significant association of GG genotype with survival time in GC patients (Table 2) . Surprisingly, we found MTR 2756 GA + GG polymorphisms (Asp868 to Gly868 switch) neutralized the effects of MTRR 66 GA + GG on prolonged survival of GC patients (Table 4, Figure 2 ). Although there is no crystal structure data on MTRR-MTR interactions, based on our data, we could deduce that Ile22 of MTRR and Asp868 of MTR are crucial for MTRR-MTR interactions. Met22 switch of MTRR may impair MTRR-MTR interaction, while three-dimensional conformation change caused by Gly868 switch of MTR may at least partially compensate and restore their interactions.
The polymorphisms of MTHFR 1298A > C and 677C > T were reported to reduce MTHFR enzymatic activity, leading to an increase in the amount of 5,10-MTHF [19] . 5,10-MTHF, a substrate for both TS and MTHFR, interacted with TS and FU to form a tertiary complex, which might strengthen the function of 5-FU. 5-FU, the most common chemotherapy drug, was used to treat many cancers including GC. TS was a primary target for 5-FU. It was reported that polymorphism of both MTHFR 1298A > C and 677C > T manifestly protected the survival of colorectal cancer patients [39] . Recent studies have demonstrated that 677T allele significantly increased the protective effect on colorectal cancer and hepatocellular cancer patients [35, 40, 41] . However, even as the polymorphisms cause a glutamine-to-alanine switch in protein sequence, we found that only MTHFR 1298CC genotype showed a comparatively favorable outcome in this study, indication of the protection of GC patient survival in a recessive way. And although polymorphisms of TS have been proposed to influence 5-FU sensitivity, the accumulated data were controversial. One study showed that patients with TS 5′-UTR 3R3R genotype had poor prognosis in neoadjuvant treated advanced GC [42] , while several other studies did not reveal any obviously prognostic differences among patients [43] [44] [45] . In term of TS 3′-UTR polymorphisms, results from different groups were also not consistent. Some showed an increase of survival for colorectal cancer patients treated with 5-FU based adjuvant chemotherapy [46, 47] , whereas others reported no obvious difference [43, 48] . In this study, no obvious relationship was found between the polymorphisms of TS 3′-UTR and 5-UTR genotypes with patient survival (Table 2) . Interestingly, we observed TS 5′UTR 2R3R + 3R3R genotypes could interact with MTHFR 1298 CA + CC polymorphisms. They jointly reduced the risk of death of GC patients although each did not show detectable effect independently (Table 4) . Patients carrying MTHFR 1298AA and TS 5-UTR 2R2R genotypes showed a relatively poor prognosis as compared to those with MTHFR 1298 CA + CC and TS 5-UTR 2R3R + 3R3R genotypes. Because 3R exhibits better translational efficiency than 2R, more 5,10-MTHF, TS and 5-FU complexes could be formed; it also displays better protective effect on GC progression to a certain extent [49] .
In summary, our findings showed that MTHFR 1298A > C and MTRR 66A > G polymorphisms were related to the survival of GC patients, which indicated that these polymorphisms may be useful biomarkers for more accurate assessments of GC prognosis in the Chinese population. Further investigations on gene-gene interactions that may enhance or neutralize the effects of each individual polymorphism are needed.
PATIENTS AND METHODS
Patient samples
All 919 GC patients were recruited at the Yixing People's Hospital (Yixing, Jiangsu Province, China) between January 1999 and December 2006. They were histopathologically diagnosed and underwent surgery. No patient had received radiotherapy or chemotherapy before surgery. The patients' clinical characteristics were Table 1 , with the maximum follow-up time of 119.0 months and the median follow-up time of 68.5 months. We classified the histopathology of GC into intestinal or diffuse types according to Lauren's Standard [50] . The TNM stages were evaluated according to the TNM classification of the American Joint Committee on Cancer (AJCC cancer staging manual, seventh edition). The retrospective cohort study was approved by the Institutional Review Board of Nanjing Medical University (Nanjing, China). All patients signed an informed consent on using clinical specimen for medical research in this study.
Determination of polymorphism incidences
Genomic DNA was extracted from paraffin sections postoperative tissues by proteinase K digestion, isopropanol extraction, and ethanol precipitation [32] . Polymorphisms were measured by SNaPshot technology with an ABI fluorescence-based assay allelic discrimination method (Applied Biosystems, Forster City, CA) or automated sequencing as previously described [51] . Primers were custom made and their sequences were listed in Supplementary Table S4 . An ABI3130 genetic analyzer was used to analyze the polymorphisms, and Genemapper4.0 software was used to determine genotypes (Applied Biosystems). Two people independently performed genotyping assays in a blind fashion. 10% random samples were selected to validate genotypes, and the results were 100% concordant.
Statistical analysis
Mean survival time was used in this study if the median survival time (MST) could not be calculated. The overall survival time of each patient was calculated from the date of surgery until death or the last followup (March 31, 2009). The correlations of each genotype and combinations of genotypes with clinicopathologic parameters were compared. Student t-test and the Pearson were employed in this study based on the types of variables. Survival analyses were carried out by Kaplan-Meier plots and log-rank tests in SPSS version 20.0 (SPSS Inc, Chicago, IL, USA). We used univariate or multivariate Cox regression analysis to estimate 95% confidence intervals (CIs), and crude/adjusted hazard ratios (HRs). All of the tests were two-sided and p < 0.05 was considered statistically significant.
